Trilaciclib Production Cost Reports

The report provides a detailed analysis essential for establishing a Trilaciclib production plant. It encompasses all critical aspects necessary for Trilaciclib production, including the cost of Trilaciclib production, Trilaciclib plant cost, Trilaciclib production costs, and the overall Trilaciclib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trilaciclib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Trilaciclib is a medicine given through a vein (intravenously) that helps protect healthy bone marrow cells during chemotherapy. It is used to reduce the incidence of chemotherapy-induced myelosuppression (bone marrow suppression) in adult patients. It is administered before chemotherapy regimens, particularly those containing platinum/etoposide or topotecan. It works by putting certain blood-forming cells into a resting state before chemotherapy. This protective effect leads to a lower risk and shorter duration of severe neutropenia, anaemia, and thrombocytopenia (common side effects of chemotherapy). It is given as a 30-minute intravenous infusion within 4 hours before chemotherapy and helps improve patient quality of life by reducing myelosuppression-related complications.

The market for Trilaciclib is driven by the rising prevalence of cancers, especially small-cell lung cancer (SCLC) and other cancers where chemotherapy-induced bone marrow damage is a concern. Its ability to protect bone marrow cells during chemotherapy, reducing side effects such as low blood cell counts, improves patient outcomes and treatment tolerability, which fuels its demand. The expanding use of combination cancer therapies and increased awareness of supportive care options also contribute its the demand. The industrial Trilaciclib procurement is affected by the high cost of the drug, regulatory approvals, and the need for intravenous administration infrastructure. Its demand is highest in North America and Europe, supported by strong healthcare infrastructure, while the Asia Pacific region also shows growth because of a rise in cancer diagnosis rates and improved healthcare access.

Raw Material for Trilaciclib Production

According to the Trilaciclib production plant project report, the key raw materials used in the production of Trilaciclib include (2-Thiomethyl-4-Chloropyrimidine)-(Piperazin-2-one)-Boc Reagent-Triflation Reagent-Diethyl silane.

Production Process of Trilaciclib

The extensive Trilaciclib production cost report consists of the following major industrial production process:

1. From 2-Thiomethyl-4-Chloropyrimidine and Piperazin-2-one: The synthesis of trilaciclib starts with a nucleophilic substitution reaction between 2-thiomethyl-4-chloropyrimidine and piperazin-2-one. This reaction requires high temperatures and long reaction times due to the low reactivity of the starting materials. After that, a Boc protection step is performed, followed by Dieckmann condensation, which gives a tricyclic compound. Next, the hydroxyl group on the pyrrole ring is removed in two steps. First, a triflate intermediate is formed, and then it is reduced with diethyl silane and Tetrakis(triphenylphosphine)palladium to produce another intermediate. The Boc group is then removed, and the thioether is oxidised to the corresponding sulfone using oxone, yielding a high-purity product. Finally, an aniline compound is treated with lithium bis(trimethylsilyl)amide and combined with the previously prepared sulfone compound through another nucleophilic substitution reaction to produce trilaciclib.

Trilaciclib has a molecular formula of C24H30N8O and a molecular weight of about 446.55 g/mol. It is a yellow, water-soluble solid in its dihydrochloride form and is formulated as a sterile lyophilised cake for intravenous infusion. It has a molecular structure containing multiple ring systems, including piperazine and pyrimidine groups. It is moderately lipophilic with a predicted LogP of around 2.7 to 3.7 and a polar surface area of 91 Ų, which affects its ability to interact with biological membranes. It contains two hydrogen bond donors and several rotatable bonds. Its pKa values indicate likely protonation under physiological conditions. It is chemically stable, non-flammable, and does not pose an explosion hazard. All these physical and chemical properties contribute to its efficacy and safety as an intravenous drug used to protect bone marrow cells during chemotherapy.